Revlimid
Celgene threatens to scale back UK clinical trial investment after CDF snub
September 4, 2015Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs
One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …
FDA in Novartis cancer drug U-turn
February 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma
The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …
Celgene gets FDA licence extension for myeloma drug
February 19, 2015Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma
The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …
Celgene UK: market access is a complex business
December 15, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce
Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …
NICE won’t back Revlimid in new setting
July 31, 2014Medical Communications, Sales and Marketing Celgene, NICE, Revlimid, Thalidomide, multiple myeloma
NICE has once again said it does not think that Celgene’s rare cancer drug Revlimid should be used on the …
Celgene ‘stops Mylan entering market’
April 6, 2014Sales and Marketing Celgene, Mylan, Revlimid, myeloma
Generic manufacturer Mylan is suing Celgene in a spat over allowing copycat versions of existing cancer drugs – Revlimid and …
Celgene ‘downplayed’ Thalomid, Revlimid risks
February 7, 2014Medical Communications, Sales and Marketing Celgene, Revlimid, Thalidomide, thalomid
A former sales representative for US pharma firm Celgene is accusing her old company of promoting two of its key …
Janssen/Pharmacyclics gain FDA nod for Imbruvica
November 14, 2013Sales and Marketing FDA, Janssen, Pharmacyclics, Revlimid, Velcade
The FDA has approved Janssen and Pharmacyclics’ Imbruvica to treat patients with mantle cell lymphoma (MCL), a rare and aggressive …
NICE no for Celgene’s Revlimid
July 11, 2013Sales and Marketing Celgene, NICE, Revlimid
NICE has issued new draft guidance not recommending Celgene’s bone marrow disorder drug Revlimid over uncertainties of its efficacy. Revlimid …
Revlimid patient scheme ‘working’
December 14, 2012Sales and Marketing Celgene, Revlimid
Celgene has issued figures which it says demonstrate the clinical value of the NICE-agreed patient access scheme for its cancer …
Celgene
January 1, 2010Research and Development, Sales and Marketing Abraxane, Celgene, Revlimid, Thalidomide
Founded in 1986, Celgene was created as a spin off from the Celanese Corporation. Two years later, the company received …
Patient wins legal battle for Revlimid
September 12, 2008Sales and Marketing Cancer, Revlimid
A cancer patient has won access to cancer drug Revlimid in a court battle with his local PCT. West Sussex …
